KZA (ASX) Registration trial

Fantastic stuff here.....perfectly illustrates why at this market cap, we are trading at multiples below the potential worth of GDC 0084.

Regardless of the future success or otherwise of our drug.....it is absolute lunacy, that the whole value of the company is just US$15m right now.

With due respect to sellers....I suggest you don't know, what you don't know. Just for example therefore, read this ; NOTE part highlighted (words from NIH)

________________________________________________________________________
US National Cancer Institute - are running a project in glioblastoma and PI3K inhibitors. See link. See part that I have highlighted - this is very timely and EXACTLY the data and information that KAZIA require for their forthcoming trial.

GDC 0084 is the only "Brain" PI3k inhibitor....our patients are very important - this constant flow of research into Pi3k brain cancers is worth millions of dollars, but more importantly, it was only a month ago the National Cancer Institute selected GDC 0084 for an expensive brain metastases trial in lung, melanoma and breast.

https://trp.cancer.gov/spores/abstracts/mdanderson_brain.htm#h04

10/10/2018
PROJECT 2: Targeting Altered Signaling Pathways in Glioblastoma with PI3K Inhibitors and Rational Combinations Project Co-Leaders: W.K. Alfred Yung, M.D. Guilio Draetta, M.D., Ph.D. The phosphoinositide-3 kinase (PI3K) signaling pathway plays an important role in tumor initiation and growth. Project 2 investigators are leaders in identifying molecular targets in glioblastoma, testing inhibitors of these targets in the laboratory, and successfully translating these drugs into clinic trials. Targeting the PI3K signal transduction pathway is part of this broader approach of combining specific inhibitors of signal transduction pathways critical to glioma development and growth. Rational combination therapies will be developed and tested, based on analysis of molecular ‘escape’ mechanisms found in tumor tissue and the glioma stem cell model, leading to strategies to block cancer cell resistance.